ReviewBioMed research international2014
Amyotrophic lateral sclerosis: a focus on disease progression.
Review in BioMed research international, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03377868 (Optic Coherence Tomography in Patients With Amyotrophic Lateral Sclerosis), which is not on this map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Optic Coherence Tomography in Patients With Amyotrophic Lateral Sclerosis
Who cites it
24 citing papers in PubMed.
- DHA/EPA (Omega-3) and LA/GLA (Omega-6) as Bioactive Molecules in Neurodegenerative Diseases.International journal of molecular sciences · 2023Review
- Dysregulated Expression of Transposable Elements in TDP-43International journal of molecular sciences · 2022Article
- SPTLC1 variants associated with ALS produce distinct sphingolipid signatures through impaired interaction with ORMDL proteins.The Journal of clinical investigation · 2022Article
- Lower and upper motor neuron involvement and their impact on disease prognosis in amyotrophic lateral sclerosis.Neural regeneration research · 2022Article
- Review
- Mediators of mitophagy that regulate mitochondrial quality control play crucial role in diverse pathophysiology.Cell biology and toxicology · 2021Review
- Inflammasome in ALS Skeletal Muscle:International journal of molecular sciences · 2021Article
- Administration of Riluzole Oral Suspension During the Different Stages of Amyotrophic Lateral Sclerosis.Frontiers in neurology · 2021Article
- Cognitive Performance of Patients with Adult 5q-Spinal Muscular Atrophy and with Amyotrophic Lateral Sclerosis.Brain sciences · 2020Article
- Chronic administration of P2X7 receptor antagonist JNJ-47965567 delays disease onset and progression, and improves motor performance in ALS SOD1Disease models & mechanisms · 2020Article
- Type XIX collagen: a promising biomarker from the basement membranes.Neural regeneration research · 2020Review
- ALS blood expression profiling identifies new biomarkers, patient subgroups, and evidence for neutrophilia and hypoxia.Journal of translational medicine · 2019Article
- Transplantation of human bone marrow stem cells into symptomatic ALS mice enhances structural and functional blood-spinal cord barrier repair.Experimental neurology · 2018Article
- Breathlessness in amyotrophic lateral sclerosis: A case report on the role of osteoporosis in the worsening of respiratory failure.Medicine · 2018Article
- Potential Role of Humoral IL-6 Cytokine in Mediating Pro-Inflammatory Endothelial Cell Response in Amyotrophic Lateral Sclerosis.International journal of molecular sciences · 2018Review
- Neurotoxicity of the Cyanotoxin BMAA Through Axonal Degeneration and Intercellular Spreading.Neurotoxicity research · 2018Article
- Combinatory Biomarker Use of Cortical Thickness, MUNIX, and ALSFRS-R at Baseline and in Longitudinal Courses of Individual Patients With Amyotrophic Lateral Sclerosis.Frontiers in neurology · 2018Article
- Detection of the Cyanotoxins L-BMAA Uptake and Accumulation in Primary Neurons and Astrocytes.Neurotoxicity research · 2018Article
- Riluzole: real-world evidence supports significant extension of median survival times in patients with amyotrophic lateral sclerosis.Degenerative neurological and neuromuscular disease · 2017Review
- Potential new complication in drug therapy development for amyotrophic lateral sclerosis.Expert review of neurotherapeutics · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Since amyotrophic lateral sclerosis (ALS) was discovered and described in 1869 as a neurodegenerative disease in which motor neuron death is induced, a wide range of biomarkers have been selected to identify therapeutic targets. ALS shares altered molecular pathways with other neurodegenerative diseases, such as Alzheimer's, Huntington's, and Parkinson's diseases. However, the molecular targets that directly influence its aggressive nature remain unknown. What is the first link in the neurodegenerative chain of ALS that makes this disease so peculiar? In this review, we will discuss the progression of the disease from the viewpoint of the potential biomarkers described to date in human and animal model samples. Finally, we will consider potential therapeutic strategies for ALS treatment and future, innovative perspectives.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.